|
1 |
Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party Enthalten in Bone marrow transplantation 28.5.2025: 1-9
|
|
|
2 |
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma Enthalten in Bone marrow transplantation 13.2.2025: 1-6
|
|
|
3 |
Management of patients undergoing CAR-T cell therapy in Germany Penack, Olaf. - Augsburg : Universität Augsburg, 2024
|
|
|
4 |
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas Liebers, Nora. - Würzburg : Universität Würzburg, 2024
|
|
|
5 |
Barriers and Facilitators in Continuous Medical Education Related to Allogeneic Stem Cell Transplantation: A Qualitative Study of Physicians Enthalten in Oncology research and treatment Bd. 47, 2024, Nr. 4: 136-144. 9 S.
|
|
|
6 |
Management of Patients Undergoing CAR-T Cell Therapy in Germany Enthalten in Oncology research and treatment Bd. 47, 2024, Nr. 3: 65-75. 10 S.
|
|
|
7 |
Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT Enthalten in Bone marrow transplantation 13.5.2024: 1
|
|
|
8 |
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC) Enthalten in Bone marrow transplantation 25.4.2024: 1-8
|
|
|
9 |
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison Enthalten in Bone marrow transplantation 21.2.2024: 1-10
|
|
|
10 |
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline Bayas, Antonios. - Kiel : Universitätsbibliothek Kiel, 2023
|
|